

American Urological Association



# Disparities in Urologic Oncology Care

Advancing Urology<sup>\*</sup>

### **Barriers to Advanced Prostate Cancer Care**

Most Frequently Reported Factors That Contribute to Variations in Advanced Prostate Cancer (APC) Care

Comorbidities - 73% Patient Compliance/Choice - 70% Health Literacy - 69% Patient Proximity to Practice - 67% Insurance Status - 65% Social Support - 64%

For patients with an initial diagnosis of APC, more respondents perceive lack of screening as very important for those from <u>underserved</u> <u>populations</u> (55%), compared to APC patients overall (40%)


N=362 Total Survey Respondents Across 47 States 239 Practicing Urologists 68 APP 42 Residents/Fellows 13 Practice Admin/Other

**Top Ranked Barriers Contributing to Disparities in Treatment of APC Patients** 


> Financial Concerns - 71% Lack of Access to Urologist/Specialist - 53% Difficulty Navigating Healthcare System - 52% Literacy Issues - 50% Lack of Patient Compliance - 47%

Subpopulations Representing a Moderate/ High Percentage of Respondents' Patient Base 75+ Years of Age - 92% Lower Educational Level - 78% From a Rural Area - 65% Uninsured - 59% Veterans - 59% African American - 56%

## Identifying and Managing Vulnerable/Underserved Patients




Urology Practices Reported a Variety of Approaches to <u>Manage</u> Vulnerable or Underserved Populations




**Prevalence of EHR to Manage APC Patients** 

Does EHR have something in place to address the lack of meeting specific goals/milestones for APC patients?




Among respondents who reported <u>not</u> leveraging EHRs, those who are younger indicate they <u>want</u> EHR trigger warnings in place to alert for unmet milestones for their APC patients



### **Formal Training on Heath Disparities**

#### Less than Half of Urology Healthcare Professionals Reported Having Formal Training in Health Disparities



management issues in accessing oral oncolytics:


- Prior authorization 63%
- Financial navigation 37%
- Copay accumulator issues 27%
- Step therapy 20%
- Unsure of the specific utilization management issues -26%

 Per AUA member surveys, awareness of manufacturer HUB services has increased from 44% in 2018, to 50% in 2021.

**Reported Use of Manufacturer HUB Services in 2021:** 


- Prior authorization and appeal assistance 71%
- Specialty pharmacy referral 63%
- Copay assistance referral 61%
- Benefit investigation and copay verification 60%
- Payment assistance program 55%

### **Respondents Perceptions of their Practices Training to Navigate Financial Hurdles Associated** with Oral Oncolytics for APC



Private Practice (46%) respondents are significantly\* more likely than those in academic/hospitals (27%) to feel comfortable navigating these issues.

### How Cost of Urology Oral Oncolytics **Affect Practices' Prescribing Patterns**





## Awareness of and Access to Clinical Trials for APC

60

One-third (34%) of !? respondents indicated they are not very aware of potential clinical trials for their APC patients







\*Significance testing was performed via Z-Test of proportions at the 95% Confidence Level.

This survey was conducted by Pfizer and American Urological Association (AUA), and conducted online through Survey Monkey from 7/21/21 through 10/5/21. The survey was distributed to AUA membership of 12,206 with valid emails. Results are based on responses from 362 AUA members. These results may not be representative of all urologic practices. Respondents included: 239 urologists, 68 NP/PAs, 42 Residents/Fellows, and 13 practice admin/other. 1. Data on File.